METRIC - Study of Glembatumumab Vedotin CDX-011 in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

Investigator: Polly Niravath, MD

Study Coordinator: Toniva Boone

Status: Enrolling Number: NCT01997333

Phone: 713.441.0686

IRB Number: Pro00012671


The main purpose of this study is to see whether CDX-011 (glembatumumab vedotin, an antibody-drug conjugate) is effective in treating patients who have advanced Triple-Negative Breast Cancer (TNBC; i.e., tumors lacking expression of estrogen, progesterone and HER2 receptors), and whose tumor cells make a protein called glycoprotein NMB (gpNMB), which CDX-011 binds to. The study will also further characterize the safety of CDX-011 treatment in this patient population.
More to Explore